ClinicalTrials.gg
CompletedNCT04708847Updated Feb 17, 2023

A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer

A Phase 1 interventional study of GYM329 and Placebo in Healthy Volunteers, sponsored by Chugai Pharmaceutical. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
Male
01

Study summary

This study will induce disuse atrophy through unilateral immobilization of the thigh and lower leg in healthy male volunteers to evaluate the PD of a single subcutaneous dose of GYM329 prior to or after unilateral thigh and lower leg immobilization.

Healthy male volunteers will receive either GYM329 or placebo by subcutaneous injection at two time points, before and after 2 weeks of unilateral thigh and lower leg immobilization, in an investigator- and subject-blinded, randomized, placebo-controlled, parallel-group design. At enrollment, all subjects will be randomized in a 1:2 ratio to either the pre-immobilization active drug group receiving a single subcutaneous dose of GYM329 before unilateral thigh and lower leg immobilization (Group A) or the pre-immobilization placebo group receiving a single subcutaneous dose of placebo before unilateral thigh and lower leg immobilization (Group B). On Day 15, subjects assigned to Group B and who completed the muscle strength assessment at Day15 will be further randomized in a 1:1 ratio to either the post-immobilization active drug group (Group B-1) or the post-immobilization placebo group (Group B-2). Group A will receive GYM329 on Day 1 and placebo on Day 15. Group B will receive placebo on Day 1. Subsequently, Group B-1 will receive GYM329 on Day 15 and Group B-2 will receive placebo on Day 15.

Muscle strength will be measured at pre-immobilization of unilateral thigh and lower leg, post-immobilization of unilateral thigh and lower leg (Day 15), Day 29, and Day 43. Subjects will be observed for 252 days after the second study treatment administration (266 days after the first study treatment administration).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written and to comply with the study protocol
  • Healthy men aged from 18 to less than 40 years at the time of consent
  • Right leg dominant
  • Agreed to limit physical activity as directed by study site staff from the time of informed consent until the end of the muscle strength evaluation period (completion of Day 43)
  • is between 18.5 and less than 25.0 at screening
  • Agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • History of congenital myopathy
  • Congenital thrombophilia
  • Previous or current VTE
  • History of hip or limb surgery, spine or spinal cord surgery, or laparotomy (excluding laparotomy for appendicitis or inguinal hernia), or laparoscopic surgery (e.g. cholecystectomy)
  • History of fracture of the pelvis or open/compound fracture of lower limb, or history of fracture within 3 years prior to screening, excluding digit fracture
  • History of severe trauma, trauma requiring surgical intervention, or trauma with organ injury which deemed as by the investigator
  • Previous or current medical condition that could lead to thrombosis as judged by the investigator
  • Angiography within 6 months before first study treatment administration
  • Current Grade ≥ 3 thermal burn or history of Grade ≥ 3 thermal burn within 3 months prior to study treatment administration
  • Unable to wear compression stockings
  • History of heparin-induced thrombocytopenia or to the LMWH and to the heparin or any other clinically significant for use of LMWH
  • Participation in bodybuilding or full time employment in a physically demanding occupation
  • Immobilization, surgery, or traumatic injury of the arm within 90 days before first study treatment administration
  • Traumatic injury of the leg within 6 months before first study treatment administration
  • Immobilization or surgery of the leg within 6 months before first study treatment administration
  • Immobilization of the leg for 2 or more weeks within 12 months before first study treatment administration
  • Contraindication for MRI
  • Habitual excessive over- or under-eating
  • Any condition that may interfere with assessment of local pain and pruritus at the injection site
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Pre-immobilization active drug group

    Subjects will receive a single subcutaneous dose of GYM329 on Day 1 and a single subcutaneous dose of placebo on Day 15.

    Drug: GYM329

  • Experimental
    Post-immobilization active drug group

    Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of GYM329 on Day 15.

    Drug: GYM329

  • Placebo comparator
    Placebo group

    Subjects will receive a single subcutaneous dose of placebo on Day 1 and a single subcutaneous dose of placebo on Day 15.

    Drug: Placebo

Interventions

  • DrugGYM329

    GYM329 subcutaneous injection

  • DrugPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Thigh muscle strength score

    Percent change in thigh muscle strength score from Day 1 to Day 15 and Day 15 to Day 29 (Thigh muscle strength score: peak isometric knee extension torque and peak isokinetic knee extension torque at 90°/s and 180°/s)

    Time frame: 28 days

Secondary outcomes

  1. Safety; Adverse event monitoring

    Incidence and severity of adverse events

    Time frame: 45 weeks

  2. Safety; Laboratory tests

    Incidence of laboratory abnormalities, based on clinical laboratory tests

    Time frame: 45 weeks

  3. Safety; Vital signs

    Abnormality in vital signs

    Time frame: 45 weeks

  4. Safety; Electrocardiogram (ECG)

    Abnormality in Electrocardiograms (ECGs)

    Time frame: 45 weeks

  5. Pharmacokinetics; Serum GYM329 concentrations

    Serum GYM329 concentrations over time

    Time frame: 45 weeks

  6. Pharmacokinetics; Cmax

    Cmax of GYM329

    Time frame: 45 weeks

  7. Pharmacokinetics; Tmax

    Tmax of GYM329

    Time frame: 45 weeks

  8. Pharmacokinetics; AUC

    AUC of GYM329

    Time frame: 45 weeks

  9. Pharmacokinetics; T1/2

    T1/2 of GYM329

    Time frame: 45 weeks

  10. Immunogenicity

    Incidence of serum anti-GYM329 antibodies

    Time frame: 45 weeks

  11. Pharmacodynamics; Muscle volume

    Changes in thigh muscle volume over time

    Time frame: 45 weeks

  12. Pharmacodynamics; Total and free latent myostatin, mature myostatin

    Changes in total and free latent myostatin, mature myostatin over time

    Time frame: 45 weeks

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Jun 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2020
First posted
Jan 14, 2021
StartActual
Feb 10, 2021
Primary completionActual
Jun 3, 2022
CompletionActual
Feb 1, 2023
Last update
Feb 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04708847
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Feb 10, 2021
Primary completion
Jun 3, 2022
Completion
Feb 1, 2023
Last update
Feb 17, 2023

Study contacts

Sponsor Chugai Pharmaceutical Co. Ltd
study director · clinical-trials@chugai-pharm.co.jp

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emugrobart

Start the discussion